Graphene Nanostructures: Pioneering Drug Delivery Vehicles for Targeting Etoposide to Cancer Cells
سال انتشار: 1404
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 140
فایل این مقاله در 18 صفحه با فرمت PDF قابل دریافت می باشد
- صدور گواهی نمایه سازی
- من نویسنده این مقاله هستم
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
JR_TIPS-11-2_002
تاریخ نمایه سازی: 6 خرداد 1404
چکیده مقاله:
Etoposide (ETO) is a formidable chemotherapeutic agent that holds great promise for individuals grappling with various forms of cancer, including testicular, prostate, bladder, stomach, and lung malignancies. While traditional chemotherapy protocols are often accompanied by significant challenges and discomfort for patients, recent advancements in nanotechnology are revolutionizing the administration of etoposide by incorporating the groundbreaking properties of graphene and its derivatives.Extensive research has highlighted the extraordinary potential of graphene as a targeted delivery system for anticancer therapies. Graphene’s unique structure and biocompatibility allow it to effectively home in on cancer cells, minimizing damage to healthy tissue. By harnessing this remarkable material, we can significantly enhance etoposide's therapeutic effectiveness while mitigating its cytotoxic side effects. This article delves into the exciting possibilities of employing graphene nanostructures as innovative vehicles for Etoposide delivery, illuminating a path toward more effective and patient-friendly cancer treatment options. The integration of advanced materials like graphene not only holds the promise of improving therapeutic outcomes but also signifies a transformative shift in the approach to cancer treatment, offering hope for a brighter future for patients and healthcare providers alike.
کلیدواژه ها:
نویسندگان
Behnaz Zamani
Biotechnology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
Khatereh Asadi
Department of Medical Nanotechnology, School of Advanced Medical Science and Technology, Shiraz University of Medical Sciences, Shiraz, Iran
Ahmad Gholami
Department of Pharmaceutical Biotechnology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran